SVB Securities analyst Mani Foroohar downgraded Decibel Therapeutics to Market Perform from Outperform with a price target of $2, down from $7.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DBTX:
- Decibel Therapeutics reports Q4 cash position $104.6M vs $162.3M last year
- Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
- Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference
- Frequency’s failure highlights Decibel’s differentiation, says H.C. Wainwright
- Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue